Legal Representation
Attorney
Frances M. Jagla
USPTO Deadlines
Next Deadline
396 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-12-08)
Due Date
December 08, 2026
Grace Period Ends
June 08, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
32 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 17, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jun 17, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Jun 17, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jun 17, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jun 17, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| May 1, 2024 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Apr 24, 2024 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | Loading... |
| Dec 8, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Nov 3, 2020 | DP1B | I | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | Loading... |
| Oct 27, 2020 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Sep 14, 2020 | IUCN | S | NOTICE OF ALLOWANCE CANCELLED | Loading... |
| Sep 14, 2020 | D1BR | I | TEAS DELETE 1(B) BASIS RECEIVED | Loading... |
| Jul 14, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| May 19, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| May 19, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 29, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Apr 9, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 9, 2020 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Apr 9, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 9, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Apr 1, 2020 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | Loading... |
| Mar 17, 2020 | GNS2 | O | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | Loading... |
| Mar 17, 2020 | GNSI | S | INQUIRY TO SUSPENSION E-MAILED | Loading... |
| Mar 17, 2020 | CNSI | R | SUSPENSION INQUIRY WRITTEN | Loading... |
| Sep 3, 2019 | GNSL | F | LETTER OF SUSPENSION E-MAILED | Loading... |
| Sep 3, 2019 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Sep 3, 2019 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Aug 26, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 21, 2019 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Aug 21, 2019 | TAEA | I | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | Loading... |
| Jun 19, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 8, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceuticals and pharmaceutical preparations for human and veterinary use for the treatment and prevention of cancer; vaccine preparations for use in connection with cancer and oncology; antibodies sold as an ingredient of pharmaceuticals for the treatment of cancer; antibodies for use in the production of active ingredients of pharmaceuticals and vaccines for use in connection with cancer and oncology; biological preparations for human medical diagnostics and analysis for use in the treatment of cancer; medical diagnostic reagents for use in connection with cancer and oncology; clinical medical reagents for use in connection with cancer and oncology; biological preparations for medical and veterinary purposes in connection with the treatment of cancer
Class 042
Research and development in the pharmaceutical and biotechnology fields in connection with cancer and oncology; research and development of medicines in the fields of cancer and oncology; scientific and technological services and research and design services in the fields of cancer and oncology; biological research, clinical research and medical research in the fields of cancer and oncology; chemical and biochemical analysis services in the fields of cancer and oncology; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology in connection with cancer and oncology; clinical research in the fields of cancer and oncology; providing medical and scientific research information in the field of pharmaceuticals in connection with cancer and oncology; Research and development services in the field of antibodies for use in connection with cancer and oncology
Classification
International Classes
005
042